United States
Pulmonary tuberculosis, oxazolidinones, phase 2b, randomised clinical trial
Tuberculosis Diagnosis, Transcriptomics, RT-qPCR Biomarker
Sputum microbiome surrogate for respiratory microbiome, anti-tuberculosis antibiotics, tuberculosis treatment, impact on microbiome, anti-tuberculosis drug development strategies.
maximum tolerable dose; high-dose rifampicin; pharmacokinetics; early bactericidal activity; dose optimization; exposure-response